TY - JOUR
T1 - Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification
AU - Knipping, Friederike
AU - Osborn, Mark J.
AU - Petri, Karl
AU - Tolar, Jakub
AU - Glimm, Hanno
AU - von Kalle, Christof
AU - Schmidt, Manfred
AU - Gabriel, Richard
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2017/3/17
Y1 - 2017/3/17
N2 - In T cells with transgenic high-avidity T cell receptors (TCRs), endogenous and transferred TCR chains compete for surface expression and may pair inappropriately, potentially causing autoimmunity. To knock out endogenous TCR expression, we assembled 12 transcription activator-like effector nucleases (TALENs) and five guide RNAs (gRNAs) from the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas9) system. Using TALEN mRNA, TCR knockout was successful in up to 81% of T cells. Additionally, we were able to verify targeted gene addition of a GFP gene by homology-directed repair at the TALEN target site, using a donor suitable for replacement of the reporter transgene with therapeutic TCR chains. Remarkably, analysis of TALEN and CRISPR/Cas9 specificity using integrase-defective lentiviral vector capture revealed only one off-target site for one of the gRNAs and three off-target sites for both of the TALENs, indicating a high level of specificity. Collectively, our work shows highly efficient and specific nucleases for T cell engineering.
AB - In T cells with transgenic high-avidity T cell receptors (TCRs), endogenous and transferred TCR chains compete for surface expression and may pair inappropriately, potentially causing autoimmunity. To knock out endogenous TCR expression, we assembled 12 transcription activator-like effector nucleases (TALENs) and five guide RNAs (gRNAs) from the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas9) system. Using TALEN mRNA, TCR knockout was successful in up to 81% of T cells. Additionally, we were able to verify targeted gene addition of a GFP gene by homology-directed repair at the TALEN target site, using a donor suitable for replacement of the reporter transgene with therapeutic TCR chains. Remarkably, analysis of TALEN and CRISPR/Cas9 specificity using integrase-defective lentiviral vector capture revealed only one off-target site for one of the gRNAs and three off-target sites for both of the TALENs, indicating a high level of specificity. Collectively, our work shows highly efficient and specific nucleases for T cell engineering.
KW - T cell therapy
KW - gene editing
KW - off target
UR - http://www.scopus.com/inward/record.url?scp=85015755082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015755082&partnerID=8YFLogxK
U2 - 10.1016/j.omtm.2017.01.005
DO - 10.1016/j.omtm.2017.01.005
M3 - Article
C2 - 28345006
AN - SCOPUS:85015755082
SN - 2329-0501
VL - 4
SP - 213
EP - 224
JO - Molecular Therapy Methods and Clinical Development
JF - Molecular Therapy Methods and Clinical Development
ER -